Literature DB >> 21325290

The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.

Lucía López-Corral1, Norma C Gutiérrez, Maria Belén Vidriales, Maria Victoria Mateos, Ana Rasillo, Ramón García-Sanz, Bruno Paiva, Jesús F San Miguel.   

Abstract

PURPOSE: Genetic aberrations detected in multiple myeloma (MM) have also been reported in the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Our aim was to investigate in depth the level of clonal heterogeneity of recurrent genetic abnormalities in these conditions. EXPERIMENTAL
DESIGN: Immunoglobulin heavy chain (IGH) translocations, 13q14 and 17p13 deletions, and 1q21 gains using FISH were evaluated in 90 MGUS, 102 high-risk SMM, and 373 MM. To this end, we not only purified plasma cells (PC) for the FISH analysis (purity > 90%), but subsequently, we examined the correlation between the proportion of PC with cytogenetic changes and the number of clonal PC present in the same sample, as measured by multiparametric flow cytometry.
RESULTS: We observed a significant difference between the proportion of clonal PC with specific genetic abnormalities in MGUS compared with SMM and in SMM compared with MM. Thus, the median proportion of PC with IGH translocations globally considered, t(11;14) and 13q deletions was significantly lower in MGUS than in SMM, and in SMM than in MM [IGH translocations: 34% vs. 57% vs. 76%; t(11;14): 38% vs. 61% vs. 81%; and 13q deletion: 37% vs. 61% vs. 74% in MGUS, SMM, and MM, respectively]. For t(4;14), the difference was significant in the comparison between MGUS/SMM and MM and for 1q between MGUS and SMM/MM.
CONCLUSIONS: This study demonstrates that the progression from MGUS to SMM, and eventually to MM, involves a clonal expansion of genetically abnormal PC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325290     DOI: 10.1158/1078-0432.CCR-10-1066

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Genomic analysis of high-risk smoldering multiple myeloma.

Authors:  Lucía López-Corral; María Victoria Mateos; Luis A Corchete; María Eugenia Sarasquete; Javier de la Rubia; Felipe de Arriba; Juan-José Lahuerta; Ramón García-Sanz; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2012-02-13       Impact factor: 9.941

2.  Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Authors:  Miki Kiyota; Tsutomu Kobayashi; Shinichi Fuchida; Mio Yamamoto-Sugitani; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Yoshiaki Chinen; Natsumi Sakamoto; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2012-03-17       Impact factor: 2.490

3.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

4.  MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Authors:  Anne Lazareth; Xiu-Yi Song; Aurelie Coquin; Stephanie Harel; Lionel Karlin; Karim Belhadj; Damien Roos-Weil; Laurent Frenzel; Jerôme Tamburini; Margaret Macro; Sylvie Chevret; Hervé Avet Loiseau; Stephane Minvielle; Jean Paul Fermand; Jean Soulier; Jean Christophe Bories; Bertrand Arnulf
Journal:  Haematologica       Date:  2015-07-23       Impact factor: 9.941

5.  Timing of treatment of smoldering myeloma: delay until progression.

Authors:  Shaji K Kumar
Journal:  Blood Adv       Date:  2018-11-13

6.  Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.

Authors:  Yoshiaki Abe; Kentaro Narita; Hiroki Kobayashi; Akihiro Kitadate; Daisuke Miura; Masami Takeuchi; Eri O'uchi; Toshihiro O'uchi; Kosei Matsue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-28       Impact factor: 9.236

Review 7.  MGUS to myeloma: a mysterious gammopathy of underexplored significance.

Authors:  Madhav V Dhodapkar
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

8.  Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.

Authors:  Gina Y Kim; Ana Gabrea; Yulia N Demchenko; Leif Bergsagel; Anna V Roschke; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

9.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 10.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.